Funds Phase 2 development of NX210c in ALS, paid in two tranches, the second tied to SEALS trial results.
- Amount
- $20.9M
- Stage
- Series A
- Announced
- 2 December 2025
- Lead
- FIDAT Ventures
- Other investors
- Cenitz, Norfoalk, FRAI AURA, FaDièse 3, Simba Santé 2
- Use of funds
- Funds Phase 2 development of NX210c in ALS, paid in two tranches, the second tied to SEALS trial results.
- Checked
- Announced by the company